ImmunoGen, Inc. researches and develops antibody-based anticancer therapeutics in the United States. It develops novel and targeted therapeutics for the treatment of cancer using its Tumor-Activated Prodrug (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. The company’s phase II product candidate include HuN901-DM1 for the treatment of CD56-expressing cancers; and phase I product candidates comprise HuC242-DM4 for the treatment of CanAg-expressing cancers, AVE9633 for the treatment of acute myeloid leukemia, and Trastuzumab-DM1 for the treatment of HER2-positive metastatic breast cancers. Its preclinical product candidates include AVE1642 for the...